{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-031568","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2023-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.387553+00:00","generated_at":"2026-06-11T00:09:28.790015+00:00","sec_items":["1.02","5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Anebulo Pharmaceuticals' Acting CFO resigns as advisory agreement with Potrero terminated","bullets":["Potrero Hill Advisors terminated Master Services Agreement with Anebulo effective Sept 28, 2023.","Sandra Gardiner resigned as Acting CFO, principal financial and accounting officer, effective Sept 28.","Gardiner offered limited transition support to successor post-termination, subject to further discussion.","Company warns of risk to financing/accounting function if successor not found by termination date."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-031568","json":"https://secwatch.observer/filing/0001493152-23-031568.json","markdown":"https://secwatch.observer/filing/0001493152-23-031568.md","text":"https://secwatch.observer/filing/0001493152-23-031568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223031568/0001493152-23-031568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223031568/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:09:28.790015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a01c90a84d","claim":"Sandra A. Gardiner resigned as Acting Chief Financial Officer at Anebulo Pharmaceuticals, Inc..","evidence_excerpt":"On August 29, 2023, in connection with the termination of the Master Services Agreement, Sandra A. Gardiner notified the Company of her resignation as the Company’s Acting Chief Financial Officer, including as the Company’s principal financial officer and principal accounting officer, effective as of the Termination Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223031568/0001493152-23-031568-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Acting Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"7fada512102a9f1b17e4a35a4d2586139fb3c8e4","claim":"Anebulo Pharmaceuticals, Inc. terminated Master Services Agreement with Potrero Hill Advisors, LLC valued at Termination of Master Services Agreement effective September 28, 2023 (effective 2023-09-28).","evidence_excerpt":"Item 1.02 Termination of a Material Definitive Agreement. On August 29, 2023, Potrero Hill Advisors, LLC (“Potrero”) provided written notice to terminate that certain Master Services Agreement, dated as of March 2, 2023, by and between Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Potrero (the “Master Services Agreement”), effective as of September 28, 2023 (the “Termination Date”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223031568/0001493152-23-031568-index.htm","confidence":0.97,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Counterparty","value":"Potrero Hill Advisors, LLC"},{"label":"Value","value":"Termination of Master Services Agreement effective September 28, 2023"},{"label":"Effective","value":"2023-09-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}